Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 435-450 , September 2006

Genetic basis of phaeochromocytoma and paraganglioma

  • Diana E. Benn, BSc, MSc (Med), PhD (Senior Hospital Scientist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +61 2 9926 7176; Fax: +61 2 9926 8484.

References 

  1. Dluhy RG. Pheochromocytoma – death of an axiom. The New England Journal of Medicine. 2002;346:1486–1488
  2. Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005;366:665–675
  3. Lack EE. Tumors of the adrenal gland and extra-adrenal paraganglia. In:  Rosai J,  Sobin LH editor. Atlas of Tumor Pathology. Washington: Armed Forces Institute of Pathology; 1997;p. 223–259
  4. Histological typing of endocrine tumours. In:  Solcia E,  Klöppel G,  Sobin LH editor. World Health Organization International Histological Classification of Tumours. 2nd edn.. London: Springer; 2000;p. 38
  5. Van Houtum WH, Corssmit EP, Douwes Dekker PB, et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. European Journal of Endocrinology. 2005;152:87–94
  6. Goldstein RE, O'Neill JA, Holcomb GW, et al. Clinical experience over 48 years with pheochromocytoma. Annals of Surgery. 1999;229:755–764
  7. Plouin PF, Gimenez-Roqueplo AP. The genetic basis of pheochromocytoma: who to screen and how?. Nature Clinical Practice. Endocrinology and Metabolism. 2006;2:60–61
  8. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. The New England Journal of Medicine. 2002;346:1459–1466
  9. Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Human Mutation. 2002;20:35–47
  10. Dannenberg H, Komminoth P, Dinjens WN, et al. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocrine Pathology. 2003;14:329–350
  11. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science. 1995;267:381–383
  12. Songyang Z, Carraway KL, Eck MJ, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995;373:536–539
  13. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. The Journal of the American Medical Association. 1996;276:1575–1579
  14. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Journal of Internal Medicine. 1995;238:343–346
  15. Nguyen L, Niccoli-Sire P, Caron P, et al. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. European Journal of Endocrinology. 2001;144:37–44
  16. Bryant J, Farmer J, Kessler LJ, et al. Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute. 2003;95:1196–1204
  17. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1999–2008
  18. Jimenez C, Gagel RF. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Hormone & IGF Research. 2004;14:S150–S157
  19. Machens A, Brauckhoff M, Holzhausen HJ, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3999–4003
  20. Latif F, Tory K, Gnarra J, et al. Identification of the von-Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320
  21. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:10595–10599
  22. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:12436–12441
  23. Kamura T, Koepp DM, Conrad MN, et al. Rbx 1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999;284:657–661
  24. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  25. Hoffman MA, Ohh M, Yang H, et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics. 2001;10:1019–1027
  26. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067
  27. Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. The Journal of Urology. 1999;162:659–664
  28. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. In:  Dahia PLM,  Eng C editor. Genetic Disorders of Endocrine Neoplasia. Frontiers of Hormone Research Series. Basel (Switzerland): Karger; 2001;p. 131–166
  29. Walther MM, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. The Journal of Urology. 1999;162:1582–1586
  30. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848–851
  31. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics. 2000;26:268–270
  32. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics. 2001;69:49–54[Erratum in: American Journal of Human Genetics 2002;70:565.]
  33. Briere JJ, Favier J, Benit P, et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics. 2005;14:3263–3269
  34. Bourgeron T, Rustin P, Chretien D, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nature Genetics. 1995;11:144–149
  35. Scheffler IE. Molecular genetics of succinate: quinone oxidoreductase in eukaryotes. Progress in Nucleic Acid Research and Molecular Biology. 1998;60:267–315
  36. Ackrell BA, Johnson MK, Gunsalus RP, et al. Structure and function of succinate dehydrogenase and fumarate reductase. In:  Muller F editors. Chemistry and Biochemistry of Flavoproteins. Boca Raton FL: CRC Press, Inc; 1990;p. 229–297
  37. Ackrell BA. Cytopathies involving mitochondrial complex II. Molecular Aspects of Medicine. 2002;23:369–384
  38. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. American Journal of Human Genetics. 2001;69:1186–1197
  39. Dahia PL, Ross KN, Wright ME, et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics. 2005;1:72–80
  40. Eisenhofer G, Huynh TT, Pacak K, et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer. 2004;11:897–911
  41. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8:155–167
  42. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77–85
  43. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Reviews. Cancer. 2005;5:857–866
  44. Heutink P, van Schothorst EM, van der Mey , et al. Further localization of the gene for hereditary paragangliomas (PGL), and evidence for linkage in unrelated families. European Journal of Human Genetics. 1994;2:148–158
  45. Baysal BE, van Schothorst EM, Farr JE, et al. Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Human Genetics. 1999;104:219–225
  46. Gimm O, Armanios M, Dziema H, et al. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research. 2000;60:6822–6825
  47. Taschner PE, Jansen JC, Baysal BE, et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes, Chromosomes & Cancer. 2001;31:274–281
  48. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. Journal of Medical Genetics. 2002;39:178–183
  49. Astuti D, Hart-Holden N, Latif F, et al. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clinical Endocrinology. 2003;59:728–733
  50. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. The Journal of the American Medical Association. 2004;292:943–951[Erratum in: The Journal of the American Medical Association 2004; 292: 1686]
  51. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. The Journal of Clinical Endocrinology and Metabolism. 2006;91:827–836
  52. Astrom K, Cohen JE, Willett-Brozick JE, et al. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Human Genetics. 2003;113:228–237
  53. Dannenberg H, van Nederveen FH, Abbou M, et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. Journal of Clinical Oncology. 2005;23:1894–1901
  54. Milunsky JM, Maher TA, Michels VV, et al. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. American Journal of Medical Genetics. 2001;100:311–314
  55. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology. 2005;23:8812–8818
  56. Hensen EF, Jordanova ES, van Minderhout IJ, et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene. 2004;23:4076–4083
  57. Dannenberg H, Dinjens WN, Abbou M, et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clinical Cancer Research. 2002;8:2061–2066
  58. Simi L, Sestini R, Ferruzzi P, et al. Phenotype variability of neural crest derived tumours in six Italian families segregating the same founder SDHD mutation Q109X. Journal of Medical Genetics. 2005;42:e52
  59. Bertherat J, Gimenez-Roqueplo AP. New insights in the genetics of adrenocortical tumors, pheochromocytomas and paragangliomas. Hormone and Metabolic Research. 2005;37:384–390
  60. Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. Familial Cancer. 2005;4:49–54
  61. McWhinney SR, Pilarski RT, Forrester SR, et al. Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. The Journal of Clinical Endocrinology and Metabolism. 2004;89:5694–5699
  62. Cascon A, Ruiz-Llorente S, Cebrian A, et al. G12S and H50R variations are polymorphisms in the SDHD gene. Genes, Chromosomes & Cancer. 2003;37:220–221
  63. Benn DE, Croxson MS, Tucker K, et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene. 2003;22:1358–1364
  64. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research. 2003;63:5615–5621
  65. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2110–2116
  66. Dahia PL. Evolving concepts in pheochromocytoma and paraganglioma. Current Opinion in Oncology. 2006;18:1–8
  67. Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. American Journal of Human Genetics. 2004;74:153–159
  68. Beck O, Fassbender WJ, Beyer P, et al. Pheochromocytoma in childhood: implication for further diagnostic procedures. Acta Paediatrica. 2004;93:1630–1634
  69. Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. The Journal of the American Medical Association. 2005;294:2057–2063[Erratum in: The Journal of the American Medical Association 2006; 295: 628]
  70. Baysal BE, Willett-Brozick JE, Filho PA, et al. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal of Medical Genetics. 2004;41:703–709
  71. Muller U, Troidl C, Niemann S. SDHC mutations in hereditary paraganglioma/pheochromocytoma. Familial Cancer. 2005;4:9–12
  72. Harris M, Winship I, Spriggs M. Controversies and ethical issues in cancer-genetics clinics. The Lancet Oncology. 2005;6:301–310
  73. Barlow-Stewart K, Burnett L. Ethical considerations in the use of DNA for the diagnosis of diseases. The Clinical Biochemist. Review. 2006;27:53–61
  74. Rosenthal MS, Pierce HH. Inherited medullary thyroid cancer and the duty to warn: revisiting Pate v. Threlkel in light of HIPAA. Thyroid. 2005;15:140–145
  75. Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. British Medical Journal. 2001;322:1052–1056
  76. Brauch H, Hoeppner W, Jahnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. The Journal of Clinical Endocrinology and Metabolism. 1997;82:4101–4104
  77. Perren A, Barghorn A, Schmid S, et al. Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene. 2002;21:7605–7608
  78. Cascon A, Ruiz-Llorente S, Fraga MF, et al. Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics. 2004;41:e30
  79. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Journal of Surgical Oncology. 2005;89:193–201
  80. Elston MS, Benn D, Robinson BG, et al. An apparently sporadic paraganglioma with an SDHB gene germline mutation presenting at age 68 years. Internal Medicine Journal. 2006;36:129–131
  81. Young WF, Abboud AL. Paraganglioma – all in the family. Editorial The Journal of Clinical Endocrinology and Metabolism. 2006;91:790–792

PII: S1521-690X(06)00051-0

doi: 10.1016/j.beem.2006.07.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 435-450 , September 2006

Article Tools

* Image Usage & Resolution